Cover: The Financial Burden from Prescription Drugs Has Declined Recently for the Nonelderly, Although It Is Still High for Many

The Financial Burden from Prescription Drugs Has Declined Recently for the Nonelderly, Although It Is Still High for Many

Published In: Health Affairs, v. 31, no. 2, Feb. 2012, p. 408-416

by Walid F. Gellad, Julie M Donohue, Xinhua Zhao, Yuting Zhang, Jessica S Banthin

View related products

Read More

Access further information on this document at Project HOPE: The People-to-People Health Foundation, Inc

This study was published in a peer-reviewed scholarly journal. The full text of the study can be found at the link above.

Research Questions

  1. How have changes in prescription drug coverage affected consumers' direct out-of-pocket expenses?

Abstract

Prescription drug spending and pharmacy benefit design have changed greatly over the past decade. However, little is known about the financial impact these changes have had on consumers. We examined ten years of nationally representative data from the Medical Expenditure Panel Survey and describe trends in two measures of financial burden for prescription drugs: out-of-pocket drug costs as a function of family income and the proportion of all out-of-pocket health care expenses accounted for by drugs. We found that although the percentage of people with high financial burden for prescription drugs increased from 1999 to 2003, it decreased from 2003 to 2007, with a slight increase in 2008. The decline is evidence of the success of strategies to lower drug costs for consumers, including the increased use of generic drugs. However, the financial burden is still high among some groups, notably those with public insurance and those with low incomes. For example, one in four nonelderly people devote more than half of their total out-of-pocket health care spending to prescription drugs. These trends suggest that the affordability of prescription drugs under the future insurance exchanges will need to be monitored, as will efforts by states to increase prescription drug copayments under Medicaid or otherwise restrict drug use to reduce public spending.

Key Findings

  • The financial burden of prescription drugs has declined recently for the nonelderly.
  • The decrease is probably due to increased use of generic drugs.
  • The financial burden remains high among those with public insurance and those with low incomes.

Recommendations

  • The affordability of prescription drugs under the new insurance exchanges mandated by the Affordable Care Act should be monitored, as should state efforts to increase prescription drug copayments under Medicaid.

Research conducted by

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.